WallStSmart

Urgent.ly Inc. Common Stock (ULY)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 100% more annual revenue ($258.90M vs $129.19M). ZEPP leads profitability with a -15.5% profit margin vs -15.8%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

ULY

Avoid

29

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -3.23

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ULY.

ZEPPUndervalued (+48.8%)

Margin of Safety

+48.8%

Fair Value

$46.82

Current Price

$18.43

$28.39 discount

UndervaluedFair: $46.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ULY1 strengths · Avg: 10.0/10
Debt/EquityHealth
-1.3110/10

Conservative balance sheet, low leverage

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

ULY4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
3.9%4/10

3.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$11.79M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : ULY

The strongest argument for ULY centers on Debt/Equity.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : ULY

The primary concerns for ULY are Revenue Growth, EPS Growth, Market Cap.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ULY profiles as a turnaround stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 29/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Urgent.ly Inc. Common Stock

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Urgent.ly Inc. is a cutting-edge leader in the on-demand roadside assistance and mobility services industry, leveraging an advanced technology platform to enhance consumer access to vehicle support. With an extensive network of service providers, the company improves customer experiences while boosting operational efficiencies in a dynamic market. As a pioneer in digital solutions for roadside assistance, Urgent.ly is well-positioned to seize growth opportunities driven by an increasing demand for real-time, app-based automotive services. Its unwavering commitment to innovation and a customer-centric approach places Urgent.ly in a strong position to expand its market presence and sustain a competitive edge in the automotive services sector.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?